Lixivaptan - Palladio Biosciences

Drug Profile

Lixivaptan - Palladio Biosciences

Alternative Names: CRTX 080; Lixar; VPA 985; WAY VPA 985

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Chiesi USA; Palladio Biosciences
  • Class Azepines; Benzamides; Small molecules
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Polycystic kidney disease
  • Discontinued Hyponatraemia

Most Recent Events

  • 27 Aug 2018 Palladio Biosciences initiates the phase II ELISA trial for Polycystic Kidney Disease in USA (PO) (NCT03487913)
  • 24 Jun 2018 Biomarkers information updated
  • 08 May 2018 Palladio Biosciences plans the phase II ELISA trial for Polycystic Kidney Disease in USA in June 2018 (PO) (NCT03487913)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top